

**MTN 043 - B-PROTECTED: Mother-Infant Pair Study of Dapivirine Ring and PrEP in Breastfeeding
Data as of December 5, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site - Infants

	Malawi Blantyre	Zimbabwe Zengeza	Uganda Kampala	SA Johannesburg	All Sites
Participants Enrolled	39	67	55	36	197
1. Physical Exam Required and Expected	115	227	165	129	636
Completed	115 (100.0%)	227 (100.0%)	165 (100.0%)	129 (100.0%)	636 (100.0%)
2. Infant Ages and Stages Assessment Required and Expected	76	134	109	71	390
Completed	76 (100.0%)	134 (100.0%)	109 (100.0%)	71 (100.0%)	390 (100.0%)
3. Dried Blood Spot for TFV-DP and FTC-TP drug levels Required and Expected (Truvada group only)	45	84	65	43	237
Completed	45 (100.0%)	84 (100.0%)	64 (98.5%)	36 (83.7%)	229 (96.6%)
Not Completed	0 (0.0%)	0 (0.0%)	1 (1.5%)	7 (16.3%)	8 (3.4%)
4. Plasma for DPV Drug levels Required and Expected (DPV group only)	141	246	202	124	713
Completed	139 (98.6%)	244 (99.2%)	202 (100.0%)	121 (97.6%)	706 (99.0%)
Not Completed	2 (1.4%)	2 (0.8%)	0 (0.0%)	3 (2.4%)	7 (1.0%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.